Generation of a panel of mutants that are resistant to standard of care therapies in a clinically relevant strain of Human cytomegalovirus for drug resistance profiling. (PubMed, Antiviral Res) - Jul 14, 2025 - "This panel consists of WT and seven mutant viruses harboring mutations that confer resistance to ganciclovir, maribavir, cidofovir, and letermovir. We observed that mutant viruses demonstrated increased EC50 concentrations for SOC inhibition, and that host directed FLS-359 demonstrated broad-spectrum antiviral activity against known SOC drug-resistant mutants. This panel represents a much-needed comparatively innovative platform for screening the efficacy of new direct-acting antivirals and host-directed antivirals against HCMV variants refractive to therapeutic interventions."
Journal • Cytomegalovirus Infection • Infectious Disease
|
|
Eain A Murphy; Kassidy Knight; Meghan F Carter; Yetunde Kayode
|